3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
18
Head & Neck
3
Gastrointestinal
3
Other solid neoplasm
1
Conditions
Colorectal Neoplasms
3
Interventions
Oxaliplatin
135
Fluorouracil
129
Gemcitabine
114
Bevacizumab
111
Specimen Handling
101
Leucovorin
101
Capecitabine
87
Magnetic Resonance Spectroscopy
81
pembrolizumab
78
Cisplatin
74
Nivolumab
70
Irinotecan
68
Cetuximab
58
130-nm albumin-bound paclitaxel
58
durvalumab
57
Paclitaxel
57
Biopsy
55
atezolizumab
42
Radiotherapy
40
Albumin-Bound Paclitaxel
36
Taxes
35
Folfox protocol
34
Carboplatin
34
Drug Therapy
28
lenvatinib
27
sintilimab
26
dehydroftorafur
26
Radiation
26
Cyclophosphamide
26
tislelizumab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
amivantamab
×
Gastrointestinal
×
90 days
×
Clear all
NCT05379595
2026-06-05
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2
Recruiting
225 enrolled
NCT06662786
2026-06-05
OrigAMI-2
Janssen Research & Development, LLC
Phase 3
Recruiting
1,000 enrolled
NCT06750094
2026-06-05
OrigAMI-3
Janssen Research & Development, LLC
Phase 3
Recruiting
700 enrolled